Meanwhile, high expression of EZH2 was associated with poor DFS in patients with ACC, BLCA, KICH, KIRP, LGG, LIHC, PRAD, and THCA, indicating that EZH2 could serve as a predictive biomarker for pan-cancer prognosis. Here, EZH2 is linked to cancer.